Stockreport

Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

Merck & Company, Inc. (new)  (MRK) 
Last merck & company, inc. (new) earnings: 4/28 06:45 am Check Earnings Report
US:NYSE Investor Relations: investors.merck.com/home/default.aspx
PDF KEYTRUDA now approved for 23 uses in 13 different types of cancer in Japan RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States [Read more]